IPO Verve Therapeutics (economic model)
Develops one-year treatments for cardiovascular disease using gene editing.
A classic pharmaceutical company with a potential drug discovery.
0,1 debt / equity, at a rate of less than 2
There is nothing to evaluate without revenue.
There is no fair share price.
IPO range: $16 -18.
I do not participate, because. the company has no revenue.